RxDoctor Payments Data

Kevin Taylor, MD

Internal Medicine · Mount Dora, FLNPI 1134233968

Payments from drug & device makers

$6,510in general payments, 2019–2025

Across 102 payments — averaging $63.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Novo Nordisk$581
  • Pfizer$508
  • Johnson & Johnson$329
  • Lilly USA, LLC$301
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,510 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$148,969
Medicare patients
229
Services billed
1,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$38,909
JardianceEmpagliflozin11$13,857
JanuviaSitagliptin Phosphate16$12,482
Ezetimibe257$7,530
Colesevelam Hcl22$2,947
Arnuity ElliptaFluticasone Furoate11$2,278
Rosuvastatin Calcium120$2,186
Levothyroxine Sodium184$1,800
SynthroidLevothyroxine Sodium20$1,730
Losartan Potassium123$1,368
Famotidine84$1,332
Amlodipine Besylate163$1,273
Bupropion Hcl SrBupropion Hcl38$1,122
Potassium Chloride43$1,043
Duloxetine Hcl40$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$508$38,90936 claims
GSKArnuity Ellipta$256$2,27811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →